Cargando…

Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group

Detalles Bibliográficos
Autores principales:	Al Tabaa, Yassine, Casasnovas, Rene Oliver, Baillet, Clio, Bachy, Emmanuel, Nicolas-Virelizier, Emmanuelle, Schiano De colella, Jean Marc, Bailly, Clement, Kanoun, Salim, Guidez, Stéphanie, Gyan, Emmanuel, Gressin, Remy, Morineau, Nadine, Ysebaert, Loic, Le Gouill, Steven, Tilly, Herve, Houot, Roch, Morschhauser, F., Cartron, Guillaume, Herbaux, Charles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368761/ https://www.ncbi.nlm.nih.gov/pubmed/37067945 http://dx.doi.org/10.1182/bloodadvances.2023009911

Ejemplares similares

Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry
por: Lemoine, Jean, et al.
Publicado: (2023)

P1133: SUB-CUTANEOUS RITUXIMAB INDUCTION FOLLOWED BY SHORT RITUXIMAB MAINTENANCE IMPROVES PFS IN PATIENTS WITH LOW-TUMOR BURDEN FOLLICULAR LYMPHOMA. FINAL RESULTS OF FLIRT PHASE III TRIAL, A LYSA STUDY.
por: Cartron, G., et al.
Publicado: (2022)

S238: CLONAL ARCHITECTURE OF RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA: AN ANCILLARY STUDY OF THE ORACLE TRIAL, A LYSA STUDY
por: Loyaux, Romain, et al.
Publicado: (2023)

S233: AXICABTAGENE CILOLEUCEL AS SECOND-LINE THERAPY FOR LARGE B-CELL LYMPHOMA IN TRANSPLANT-INELIGIBLE PATIENTS: FINAL ANALYSIS OF ALYCANTE, A PHASE 2 LYSA STUDY
por: Houot, Roch, et al.
Publicado: (2023)

Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group
por: Bonnet, Christophe, et al.
Publicado: (2022)

P1079: VERY LONG-TERM FOLLOW-UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY.
por: Sarkozy, Clementine, et al.
Publicado: (2023)

P1123: EARLY CTDNA CLEARANCE AFTER CAR T-CELL INFUSION PREDICTS OUTCOME IN PATIENTS WITH LARGE B-CELL LYMPHOMA: RESULTS FROM ALYCANTE, A PHASE 2 LYSA STUDY
por: Delfau-Larue, Marie-Helene, et al.
Publicado: (2023)

S226: EFFICACY OF ANTI-PD1 THERAPY IN RELAPSED OR REFRACTORY EXTRANODAL NK/T CELL LYMPHOMA: A MATCHED COHORT ANALYSIS FROM THE LYSA
por: Marouf, Amira, et al.
Publicado: (2023)

Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years
por: Jullien, Maxime, et al.
Publicado: (2021)

Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis
por: Thieblemont, Catherine, et al.
Publicado: (2023)

FDG-PET/CT in Lymphoma: Where Do We Go Now?
por: Al Tabaa, Yassine, et al.
Publicado: (2021)

P1090: LONG TERM FOLLOW-UP OF UNTREATED/RELAPSING MCL PATIENTS WITH THE IBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX COMBINATION.
por: Le Gouill, Steven, et al.
Publicado: (2023)

Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group
por: Aubrais, Raphaelle, et al.
Publicado: (2022)

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R(2)) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
por: Morschhauser, Franck, et al.
Publicado: (2022)

Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study
por: Busson, Raphaël, et al.
Publicado: (2019)

Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial
por: Houot, Roch, et al.
Publicado: (2023)

Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial
por: Houot, Roch, et al.
Publicado: (2023)

Central nervous system relapse in patients over 80 years with diffuse large B‐cell lymphoma: an analysis of two LYSA studies
por: Cabannes‐Hamy, Aurélie, et al.
Publicado: (2018)

Clinical presentation, outcome, and prognostic markers in patients with intravascular large B‐cell lymphoma, a lymphoma study association (LYSA) retrospective study
por: Bonnet, Antoine, et al.
Publicado: (2022)

Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study
por: Paunescu, Alexandra-Cristina, et al.
Publicado: (2021)

Correction to: Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study
por: Paunescu, Alexandra‑Cristina, et al.
Publicado: (2021)

A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the “REal world dAta in LYmphoma and survival in adults” (REALYSA) cohort
por: Ghesquières, Hervé, et al.
Publicado: (2021)

Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study
por: Reboursiere, Emilie, et al.
Publicado: (2016)

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
por: Bachy, Emmanuel, et al.
Publicado: (2022)

ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study
por: Sibon, David, et al.
Publicado: (2022)

P1146: TRANSFUSION NEEDS AFTER CD19 CAR T-CELLS FOR LARGE B-CELL LYMPHOMA: PREDICTIVE FACTORS AND IMPACT ON OUTCOME. A DESCAR-T STUDY.
por: Vic, Samuel, et al.
Publicado: (2023)

Deep Learning Approach to Automatize TMTV Calculations Regardless of Segmentation Methodology for Major FDG-Avid Lymphomas
por: Revailler, Wendy, et al.
Publicado: (2022)

Yeast Derived LysA2 Can Control Bacterial Contamination in Ethanol Fermentation
por: Kim, Jun-Seob, et al.
Publicado: (2018)

A Second Endolysin Gene Is Fully Embedded In-Frame with the lysA Gene of Mycobacteriophage Ms6
por: Catalão, Maria João, et al.
Publicado: (2011)

Development of Phage Lysin LysA2 for Use in Improved Purity Assays for Live Biotherapeutic Products
por: Dreher-Lesnick, Sheila M., et al.
Publicado: (2015)

Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma
por: Houot, Roch, et al.
Publicado: (2022)

[(18)F]FDG-PET/CT in Hodgkin Lymphoma: Current Usefulness and Perspectives
por: Kanoun, Salim, et al.
Publicado: (2018)

P1186: A LARGE FRENCH REAL WORLD MULTICENTRIC PROSPECTIVE COHORT OF PATIENTS WITH LYMPHOMA (REALYSA STUDY): DESCRIPTION OF THE DIFFUSE LARGE B CELL LYMPHOMA PATIENTS IN REAL WORLD IN FRANCE
por: Ghesquieres, H., et al.
Publicado: (2022)

Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?
por: Houot, Roch, et al.
Publicado: (2020)

c-Rel Is the Pivotal NF-κB Subunit in Germinal Center Diffuse Large B-Cell Lymphoma: A LYSA Study
por: Faumont, Nathalie, et al.
Publicado: (2021)

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study
por: Bachy, Emmanuel, et al.
Publicado: (2019)

BET Family Protein BRD4: An Emerging Actor in NFκB Signaling in Inflammation and Cancer
por: Hajmirza, Azadeh, et al.
Publicado: (2018)

Controversies in the Treatment of Peripheral T-cell Lymphoma
por: Bachy, Emmanuel, et al.
Publicado: (2020)

High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline
por: Rossi, Cédric, et al.
Publicado: (2022)

Nonclassical Monocytes Are Prone to Migrate Into Tumor in Diffuse Large B-Cell Lymphoma
por: Le Gallou, Simon, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bmphj3g1c3quha05npoop1oqj0